The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Open accessAbstract
Chimeric antigen receptor (CAR)-modified T cells and bispecific T cell-engaging antibodies have demonstrated dramatic clinical responses in recent clinical trials. The hallmark of these novel highly active immunotherapies is nonphysiologic T cell activation, which has correlated not only with greatly increased efficacy but also with notable toxicity in some cases. We and others have observed a cytokine release syndrome (CRS), which correlates with both toxicity and efficacy in patients receiving T cell-engaging therapies. In addition to elevations in effector cytokines, such as interferon-γ, cytokines associated with hemophagocytic lymphohistiocytosis or macrophage activation syndrome, such as interleukin (IL)-10 and IL-6, may also be markedly elevated. Whereas corticosteroids may control some of these toxicities, their potential to block T cell activation and abrogate clinical benefit is a concern. Detailed studies of T cell proliferation and the resultant immune activation produced by these novel therapies have led to more targeted approaches that have the potential to provide superior toxicity control without compromising efficacy. One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab. We will review the pathophysiology and management options for CRS associated with T cell-engaging therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.
Iyer, S. S., & Cheng, G. (2012) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v32.i1.30 · Cited by 1,611
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112802 · Cited by 763
Martin, P. J., Rizzo, J. D., Wingard, J. R., Ballen, K., Curtin, P. T., Cutler, C., Litzow, M. R., Nieto, Y., Savani, B. N., Schriber, J. R., et al. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.04.005 · Cited by 641
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Self-citationKochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH
Zhang, K., Jordan, M. B., Marsh, R. A., Johnson, J. A., Kissell, D., Meller, J., Villanueva, J., Risma, K. A., Wei, Q., Klein, P. S., et al. (2011) · Blood · doi:10.1182/blood-2011-07-370148 · Cited by 428
Yokota, S., Miyamae, T., Imagawa, T., Iwata, N., Katakura, S., Mori, M., Woo, P., Nishimoto, N., Yoshizaki, K., & Kishimoto, T. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20944 · Cited by 370
The German etanercept registry for treatment of juvenile idiopathic arthritis
Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H. J., Hospach, T., Huppertz, H. I., Keitzer, R., Küster, R. M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.014886 · Cited by 318
Gene modulation and immunoregulatory roles of Interferonγ
Saha, B., Jyothi Prasanna, S., Chandrasekar, B., & Nandi, D. (2010) · Cytokine · doi:10.1016/j.cyto.2009.11.021 · Cited by 300
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Diagnostic Accuracy of a Specific Cytokine Pattern in Hemophagocytic Lymphohistiocytosis in Children
Xu, X.-J., Tang, Y.-M., Song, H., Yang, S.-L., Xu, W.-Q., Zhao, N., Shi, S.-W., Shen, H.-P., Mao, J.-Q., Zhang, L.-Y., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.11.046 · Cited by 225
Woo, P., Wilkinson, N., Prieur, A.-M., Southwood, T., Leone, V., Livermore, P., Wythe, H., Thomson, D., & Kishimoto, T. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1826 · Cited by 213
Tang, Y., Xu, X., Song, H., Yang, S., Shi, S., Wei, J., Pan, B., Zhao, F., Liao, C., & Luo, C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07298.x · Cited by 186
Hemophagocytic lymphohistiocytosis: updates and evolving concepts
Risma, K., & Jordan, M. B. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834ec9c1 · Cited by 184
Verbsky, J. W., & White, A. J. (2004) · PubMed · Cited by 168
Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review
Singh, J. A., Beg, S., & Lopez-Olivo, M. (2011) · Journal of Rheumatology · doi:10.3899/jrheum.100717 · Cited by 156
Brandl, C., Haas, C., d’Argouges, S., Fisch, T., Kufer, P., Brischwein, K., Prang, N. S., Bargou, R. C., Suzich, J., Baeuerle, P. A., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0298-z · Cited by 148
Genotype–phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations
Trizzino, A., Stadt, U. Z., Ueda, I., Risma, K., Janka, G., Ishii, E., Beutel, K., Sümegi, J., Cannella, S., Pende, D., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.052670 · Cited by 143
Shimizu, M., Nakagishi, Y., Kasai, K., Yamasaki, Y., Miyoshi, M., Takei, S., & Yachie, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.02.006 · Cited by 131
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C. L., Orentas, R. J., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 128
Self-citationOlin, R. L., Nichols, K. E., Naghashpour, M., Wasik, M. A., Shelly, B. K., Stadtmauer, E. A., & Vogl, D. T. (2008) · American Journal of Hematology · doi:10.1002/ajh.21236 · Cited by 66
Huang, Z., Xu, J., Yuelin, S., Qiang, Q., Chunyan, L., Xie, Z., & Kunling, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23216 · Cited by 44
Tamura, K., Kanazawa, T., Tsukada, S., Kobayashi, T., Kawamura, M., & Morikawa, A. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21660 · Cited by 44
α-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis
Tomaske, M., Amon, O., Bosk, A., Handgretinger, R., Schneider, E. M., & NIETHAMMER, D. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.1294 · Cited by 32
Antibody Therapy for Acute Lymphoblastic Leukemia
Portell, C. A., & Advani, A. S. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0120-7 · Cited by 15
Cited by
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Metadata
- Authors
- Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A.
- Venue
- The Cancer Journal
- Published
- 2014-03
- Volume
- 20
- Issue
- 2
- Pages
- 119-122
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W1985579610
- Cited by
- 752
- References
- 40
- FWCI
- 24.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.